http://orcid.org/0000-0002-6472-1419
Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Tao Wang, Yanan Li, Shuai Miao, Chunxiao Yang, Wei Xie, Huijuan Yuan, Wenhao Bai, Han Xiao & Shengyuan Yu. (2023) A Bibliometric and Scientific Knowledge Map Study of Migraine Treatment from 2013 to 2022. Journal of Pain Research 16, pages 3169-3184.
Read now
Read now
Shigekazu Kitamura, Noboru Imai, Yuka Tanji, Akichika Ozeki & Mika Komori. (2023) Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study. Journal of Pain Research 16, pages 1725-1738.
Read now
Read now
Xing Wang, Jinlei Song & Chao You. (2023) Efficacy and safety of galcanezumab for migraine: evidences from direct and indirect comparisons. International Journal of Neuroscience 133:8, pages 925-933.
Read now
Read now
Koichi Hirata, Yasuhiko Matsumori, Yuka Tanji, Rashna Khanna, Akichika Ozeki & Mika Komori. (2023) Safety profile of lasmiditan in patients with migraine in an Asian population. Expert Opinion on Drug Safety 22:1, pages 91-101.
Read now
Read now
Eleonora De Matteis, Simona Sacco & Raffaele Ornello. (2022) Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes. Therapeutics and Clinical Risk Management 18, pages 359-378.
Read now
Read now
Yoichiro Hashimoto, Mika Komori, Yuka Tanji, Akichika Ozeki & Koichi Hirata. (2022) Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opinion on Drug Safety 21:12, pages 1495-1503.
Read now
Read now
Abouch Krymchantowski, Raimundo Pereira Silva-Néto, Carla Jevoux & Ana Gabriela Krymchantowski. (2022) Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgraduate Medicine 134:6, pages 598-602.
Read now
Read now
Yanqing Zhao, Li Huang, Meijuan Liu, Han Gao & Wentao Li. (2021) Scientific Knowledge Graph of Acupuncture for Migraine: A Bibliometric Analysis from 2000 to 2019. Journal of Pain Research 14, pages 1985-2000.
Read now
Read now
Flavia Lo Castro, Simona Guerzoni & Lanfranco Pellesi. (2021) Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug, Healthcare and Patient Safety 13, pages 233-240.
Read now
Read now
Abimael González-Hernández, Bruno A. Marichal-Cancino & Carlos M. Villalón. (2021) The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opinion on Drug Metabolism & Toxicology 17:10, pages 1223-1235.
Read now
Read now
Bruno A. Marichal-Cancino, Abimael González-Hernández, Raquel Guerrero-Alba, Roberto Medina-Santillán & Carlos M. Villalón. (2021) A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Review of Neurotherapeutics 21:9, pages 1035-1050.
Read now
Read now
Abimael González-Hernández, Miguel Condés-Lara, Enrique García-Boll & Carlos M. Villalón. (2021) An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 17:2, pages 179-199.
Read now
Read now
Eduardo Rivera-Mancilla, Carlos M. Villalón & Antoinette MaassenVanDenBrink. (2020) CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opinion on Drug Safety 19:10, pages 1237-1250.
Read now
Read now
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, Valerio Spuntarelli, Paolo Martelletti & Simona Sacco. (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Review of Neurotherapeutics 20:6, pages 627-641.
Read now
Read now